The use of chemosensitizers to enhance the response to conventional therapy in triple-negative breast cancer patients

[1]  M. Iriti,et al.  Rutin, a Quercetin Glycoside, Restores Chemosensitivity in Human Breast Cancer Cells , 2017, Phytotherapy research : PTR.

[2]  Y. Hsu,et al.  A novel 4-arm DNA/RNA Nanoconstruct triggering Rapid Apoptosis of Triple Negative Breast Cancer Cells within 24 hours , 2017, Scientific Reports.

[3]  Zhi-rui Zhou,et al.  The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy , 2017, Acta Pharmacologica Sinica.

[4]  Jing Wang,et al.  AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers , 2016, Molecular Cancer Research.

[5]  Mandip Singh,et al.  Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. , 2016, Experimental cell research.

[6]  Xianting Ding,et al.  Curcumin in Treating Breast Cancer , 2016, Journal of laboratory automation.

[7]  H. Sasano,et al.  Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification , 2016, Expert opinion on therapeutic targets.

[8]  Xiaoyuan Chen,et al.  A nanoparticulate pre-chemosensitizer for efficacious chemotherapy of multidrug resistant breast cancer , 2016, Scientific Reports.

[9]  R. Paulmurugan,et al.  Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy. , 2016, Nanomedicine.

[10]  I. Kwon,et al.  Co-delivery of chemosensitizing siRNA and an anticancer agent via multiple monocomplexation-induced hydrophobic association. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[11]  P. Thulasiraman,et al.  Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cells , 2014, BMC Cancer.

[12]  Jenny C. Chang,et al.  Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells , 2014, Oncotarget.

[13]  A. Sood,et al.  Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (−) and ER (+) Breast Cancer , 2013, Molecular therapy. Nucleic acids.

[14]  R. J. Anto,et al.  Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil , 2013, Cell Death and Disease.

[15]  Lei He,et al.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.

[16]  Shuang Huang,et al.  Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. , 2011, European journal of cancer.

[17]  Yu Shyr,et al.  RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells , 2010, Breast Cancer Research.

[18]  W. Symmans,et al.  B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells , 2006, Molecular Cancer Therapeutics.

[19]  H. Cheng,et al.  Chemosensitization of breast carcinoma cells with the use of bcl-2 antisense oligodeoxynucleotide. , 2004, Breast.

[20]  Jonathan Hall,et al.  Bcl-2/bcl-xL Bispecific Antisense Treatment Sensitizes Breast Carcinoma Cells to Doxorubicin, Paclitaxel and Cyclophosphamide , 2002, Breast Cancer Research and Treatment.

[21]  L. Mayer,et al.  Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression , 2000, Breast Cancer Research and Treatment.

[22]  C. Leonetti,et al.  The future of antisense therapy: combination with anticancer treatments , 2003, Oncogene.

[23]  L. Mayer,et al.  Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.